

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

PROPOSED SHARE REPURCHASE

This announcement is made voluntarily by 3SBio Inc. (the “**Company**”).

References are made to the circular of the Company dated 22 May 2023 and the announcement of the Company dated 20 June 2021 in relation to, among others, the general mandate to repurchase shares of the Company (the “**Shares**”) granted by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting of the Company held on 20 June 2023 (the “**2023 Repurchase Mandate**”). The board (the “**Board**”) of directors of the Company (the “**Directors**”) hereby announces that it intends to exercise its powers under the 2023 Repurchase Mandate and/or the general mandate to repurchase Shares granted by the Shareholders at the annual general meeting of the Company scheduled to be held on 25 June 2024 (the “**2024 Repurchase Mandate**”) (as the case may be) to repurchase Shares in the open market at appropriate timing (the “**Proposed Share Repurchase**”). Pursuant to the 2023 Repurchase Mandate, the Company is allowed to repurchase up to 243,892,041 Shares, being 10% of the total issued Shares as at the date of the annual general meeting of the Company held on 20 June 2023, on The Stock Exchange of Hong Kong Limited. The 2023 Repurchase Mandate will expire at the conclusion of the annual general meeting of the Company scheduled to be held on 25 June 2024 (the “**2024 AGM**”). The Directors intend to seek the 2024 Repurchase Mandate from the Shareholders at the 2024 AGM.

The financial position of the Company is solid and healthy. The Board considers that the current trading price of the Shares does not reflect their intrinsic value and the actual business prospects and that it presents a good opportunity for the Company to repurchase Shares. The Board believes the Proposed Share Repurchase and subsequent cancellation of the repurchased Shares can enhance the value of the Shares thereby improving the return to the Shareholders. In addition, the Proposed Share Repurchase reflects the Company’s recognition of its own value and its confidence in the long-term prospects of the industry. The Board believes that the Proposed Share Repurchase is in the interests of the Company and its Shareholders as a whole.

Shareholders and potential investors should note that, as at the date of this announcement, the Company has not repurchased any Shares. The exercise of the 2023 Repurchase Mandate and/or the 2024 Repurchase Mandate (as the case may be) by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share repurchases or whether or not the Company will make any further repurchases at all. Therefore, Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Hong Kong SAR, PRC
21 March 2024

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi, Mr. NG, Joo Yeow Gerry and Dr. ZHANG Dan as independent non-executive Directors.